The two new therapies represent the first products Accord BioPharma has manufactured end-to-end within its own corporate structure. OSVYRTI is indicated for various forms of osteoporosis, while JUBEREQ focuses on preventing skeletal-related events in patients with multiple myeloma or bone metastases, as well as treating giant cell tumor of bone. Both drugs arrive as the U.S. healthcare system faces mounting pressure from rising fracture rates, which are expected to reach 3.2 million annually by 2040.
Accord BioPharma Launches Interchangeable Denosumab Biosimilars
Expanding the market for bone health treatments, Accord BioPharma has officially released OSVYRTI and JUBEREQ, two interchangeable biosimilars for Prolia and XGEVA. The launch signals a strategic push by the U.S. specialty division of Intas Pharmaceuticals to lower costs for patients managing osteoporosis and cancer-related bone complications.
Financial accessibility remains a primary driver for the rollout. With Medicare Part B spending on denosumab products exceeding $2 billion in 2024, the company has priced OSVYRTI at $1,800.41 per syringe and JUBEREQ at $3,311.75 per vial. Accord has secured preferred status for both brands on several Cigna commercial pharmacy benefit lists, and through its AccordCares support program, eligible patients may access the treatments for as little as $0. This release is a core component of the firm's broader roadmap to introduce 20 biosimilar products to the U.S. market by 2030.
:max_bytes(150000):strip_icc()/bday3-153fc5a613f444c3bdee1e7c40f8cc52.jpg)
Comments (0)
No comments yet. Be the first!